Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be th

Auteurs : Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, van t Veer L, Rutgers E, Piccart-Gebhart M, Stork-Sloots L, Dell orto P, Glas A, Cardoso F
Année : 2016
Journal : Breast Cancer Res Treat
Volume : 155(3)
Pages : 463-9

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Auteurs : Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart-Gebhart M, Gelber Rd
Année : 2016
Journal : Breast Cancer Res Treat
Volume : 155
Pages : 127-32

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Auteurs : Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, Mcfadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber Rd, Perez EA
Année : 2016
Journal : J Clin Oncol
Volume : 34(10)
Pages : 1034-42

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Auteurs : Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart-Gebhart M, Michiels S, Sotiriou C
Année : 2016
Journal : JAMA Oncol
Volume : 2(2)
Pages : 217-24

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Auteurs : Hortobagyi GN, Chen D, Piccart-Gebhart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J
Année : 2016
Journal : J Clin Oncol
Volume : 34(5)
Pages : 419-26

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.

Auteurs : Fadoukhair Z, Zardavas D, Chad MA, Goulioti T, Aftimos P, Piccart-Gebhart M
Année : 2016
Journal : Oncogene
Volume : 35(14)
Pages : 1743-9

Frequent incidence of BARD1 truncating mutations in germline DNA from triple negative breast cancer patients.

Auteurs : De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart M, Pauwels I, Teugels E
Année : 2016
Journal : Clin. Genet.
Volume : 89(3)
Pages : 336-40.

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.

Auteurs : Amzerin M, Mokrim M, Errihani H, Piccart-Gebhart M
Année : 2015
Journal : J Med Case Rep
Volume : 9
Pages : 5

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Année : 2015
Journal : Ann Oncol
Volume : 26
Pages : 1547-73

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.

Auteurs : Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart-Gebhart M, Flamen P
Année : 2015
Journal : PLoS One
Volume : 10
Pages : e0138341

Neoadjuvant Therapy for Breast Cancer.

Auteurs : Zardavas D, Piccart-Gebhart M
Année : 2015
Journal : Annu. Rev. Med.
Volume : 66
Pages : 31-48

An update on PARP inhibitors-moving to the adjuvant setting.

Auteurs : Sonnenblick A, de Azambuja E, Azim HA, Piccart-Gebhart M
Année : 2015
Journal : Nat Rev Clin Oncol
Volume : 12(1)
Pages : 27-41

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart-Gebhart M, Sotiriou C
Année : 2015
Journal : Oncotarget
Volume : 6
Pages : 30306-16

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Auteurs : Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart-Gebhart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V
Année : 2015
Journal : Cell Rep
Volume : 13
Pages : 277-89

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Auteurs : Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart M, Scaltriti M, Baselga J
Année : 2015
Journal : Ann Oncol
Volume : 26
Pages : 1494-500

Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

Auteurs : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Année : 2015
Journal : Eur J Cancer
Volume : 51
Pages : 2517-24

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Auteurs : Zardavas D, Fouad TM, Piccart-Gebhart M
Année : 2015
Journal : Breast
Volume : 24 Suppl 2
Pages : S143-8

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart-Gebhart M, Sotiriou C
Année : 2015
Journal : BMC Med
Volume : 13(1)
Pages : 177

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Auteurs : Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart-Gebhart M, Crown J
Année : 2015
Journal : Eur. J. Cancer
Volume : 51(12)
Pages : 1481-9

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

Auteurs : OSullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber Rd
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(24)
Pages : 2600-8